 |
EPO rejection of WARF patent could hit embryonic stem cell work
Monday 1 December 2008
Ian Schofield - Analyst
In a move that will come as a blow to companies seeking to develop new therapies based on human embryonic stem cells, the European Patent Office has declared that patents will not be granted on stem cells that are produced by destroying a human embryo.
The decision finally puts an end to a lengthy case involving a human embryonic stem (hES) cell patent filed with the EPO in 1995 by the Wisconsin Alumni Research Foundation (WARF).
In July 2004, an examining division of the EPO refused to grant the patent, saying it was inconsistent with the European Patent Convention, mainly because its production necessarily involved the destruction of a human embryo.
Login to view the full article
- Not a subscriber? Request a FREE trial
- Subscribe to Scrip
- Email to a friend
Comments
No Comments Yet
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
